Señalización JAK / STAT
Los inhibidores de la señalización JAK/STAT son compuestos que interrumpen la vía de la cinasa Janus (JAK) y del transductor y activador de la transcripción (STAT), la cual está involucrada en la señalización de citoquinas, el crecimiento celular y la respuesta inmunitaria. Estos inhibidores son herramientas importantes para estudiar la regulación de esta vía y su papel en diversas enfermedades, como el cáncer, los trastornos inmunitarios y las condiciones inflamatorias. Los inhibidores de JAK/STAT también están siendo desarrollados como terapias dirigidas para estas enfermedades. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de la señalización JAK/STAT para apoyar su investigación en biología molecular, oncología e inmunología.
Subcategorías de "Señalización JAK / STAT"
Productos de "Señalización JAK / STAT"
Ordenar por
Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Fórmula:C20H18FN5O3Pureza:98.05%Forma y color:SolidPeso molecular:395.39Pim-1/2 kinase inhibitor 1
CAS:Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.Fórmula:C11H9NO3SPureza:99.89%Forma y color:SolidPeso molecular:235.26JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Fórmula:C20H18FN5O3SPureza:98.88%Forma y color:SolidPeso molecular:427.45Ref: TM-T13571
1mg87,00€5mg177,00€10mg260,00€25mg429,00€50mg605,00€100mg815,00€500mg1.624,00€1mL*10mM (DMSO)188,00€JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Fórmula:C17H19F2N7OSPureza:98%Forma y color:SolidPeso molecular:407.44Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Forma y color:SolidPeso molecular:504.49ITK inhibitor 2
CAS:ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.Fórmula:C25H33N5O2Forma y color:SolidPeso molecular:435.56TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFórmula:C28H32N4O3SPureza:97.38% - 99.1%Forma y color:SolidPeso molecular:504.64(2R)-Octyl-α-hydroxyglutarate
CAS:(2R)-Octyl-α-hydroxyglutarate ((2R)-Octyl-2-HG) is a D-isomer 2-Hydroxyglutarate modified form.Fórmula:C13H24O5Forma y color:SolidPeso molecular:260.33Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C21H21ClFN7Pureza:99.55%Forma y color:SolidPeso molecular:425.89Ref: TM-T12266L2
1mg77,00€5mg165,00€10mg240,00€25mg408,00€50mg562,00€100mg800,00€200mg1.074,00€1mL*10mM (DMSO)177,00€G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Fórmula:C22H19F2NO3Pureza:97.30%Forma y color:SolidPeso molecular:383.39Ref: TM-T8742
1mg50,00€5mg97,00€10mg145,00€25mg259,00€50mg374,00€100mg523,00€200mg710,00€1mL*10mM (DMSO)105,00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Fórmula:C16H13Cl2N3O2Pureza:98.77%Forma y color:SolidPeso molecular:350.2RO495
CAS:RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assaysFórmula:C17H14Cl2N6OPureza:97.94%Forma y color:SolidPeso molecular:389.24Ref: TM-T22416
1mg64,00€2mg87,00€5mg117,00€10mg183,00€25mg354,00€50mg520,00€100mg702,00€200mg944,00€1mL*10mM (DMSO)140,00€JAK-IN-5 hydrochloride
CAS:JAK-IN-5 hydrochloride is a JAK inhibitor [1].Fórmula:C27H32ClFN6OForma y color:SolidPeso molecular:511.03Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Fórmula:C19H19F2N7O3Forma y color:SolidPeso molecular:431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Fórmula:C28H38N6O5SPureza:98%Forma y color:SolidPeso molecular:570.7SGI-1776
CAS:SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.Fórmula:C20H22F3N5OPureza:100% - 99.84%Forma y color:SolidPeso molecular:405.42Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Fórmula:C25H26F2N6O2Pureza:98.71%Forma y color:SoildPeso molecular:480.51Ref: TM-T67907
1mg96,00€2mg139,00€5mg227,00€10mg354,00€25mg653,00€50mg938,00€100mg1.454,00€500mg2.822,00€JAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Fórmula:C14H10ClN3OS2Pureza:99.38%Forma y color:SolidPeso molecular:335.83JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Fórmula:C25H32N8O2Pureza:99.64%Forma y color:SolidPeso molecular:476.57WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Fórmula:C17H14BrN3OPureza:98.92% - 99.73%Forma y color:SolidPeso molecular:356.22JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFórmula:C22H17FN6O2SPureza:98%Forma y color:SolidPeso molecular:448.47Dual Cathepsin L/JAK-IN-1
CAS:DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Fórmula:C19H18ClN5Forma y color:SolidPeso molecular:351.833GDC-0339
CAS:GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.Fórmula:C20H22F3N7OSForma y color:SolidPeso molecular:465.5Decernotinib
CAS:Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Fórmula:C18H19F3N6OPureza:100% - 99.45%Forma y color:SolidPeso molecular:392.38Ref: TM-T2636
1mg38,00€2mg52,00€5mg79,00€10mg110,00€25mg217,00€50mg329,00€100mg494,00€200mg705,00€1mL*10mM (DMSO)88,00€Pim1/AKK1-IN-1
CAS:Pim1/AKK1-IN-1: LKB1/AAK1 inhibitor with Kd 35/53/75/380 nM for Pim1/AKK1/MST2/LKB1, also targets MPSK1, TNIK.Fórmula:C20H13N5OPureza:97.84% - 98.69%Forma y color:SolidPeso molecular:339.35Ref: TM-T5093
1mg89,00€2mg131,00€5mg183,00€10mg278,00€25mg490,00€50mg710,00€100mg998,00€1mL*10mM (DMSO)202,00€Pacritinib
CAS:Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Fórmula:C28H32N4O3Pureza:99.25% - 99.49%Forma y color:SolidPeso molecular:472.58CX-6258
CAS:CX-6258 is an orally valid Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor. It has good biological activity and kinase specificity.Fórmula:C26H24ClN3O3Pureza:95.88%Forma y color:SolidPeso molecular:461.94Ref: TM-T1834
1mg37,00€5mg80,00€10mg106,00€25mg208,00€50mg311,00€100mg472,00€200mg658,00€1mL*10mM (DMSO)81,00€Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Forma y color:SolidPeso molecular:469.94Ref: TM-T2638
5mg51,00€10mg88,00€25mg160,00€50mg296,00€100mg469,00€500mg1.035,00€1mL*10mM (DMSO)57,00€JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Fórmula:C26H33N7OPureza:98.71%Forma y color:SolidPeso molecular:459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Fórmula:C20H28FN7Pureza:98%Forma y color:SolidPeso molecular:385.48JBJ-04-125-02
CAS:JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFórmula:C17H20N6OPureza:98.81%Forma y color:SolidPeso molecular:324.38Quercetagetin
CAS:Quercetagetin, a flavonoid from Citrus unshiu, inhibits pim-1 kinase (IC50: 0.34 μM), cell-permeable.Fórmula:C15H10O8Pureza:99.65% - 99.76%Forma y color:SolidPeso molecular:318.24Ref: TM-T8114
1mg88,00€5mg202,00€10mg303,00€25mg510,00€50mg733,00€100mg998,00€500mg1.985,00€1mL*10mM (DMSO)213,00€DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Fórmula:C26H35N7O5Forma y color:SolidPeso molecular:525.6Pumecitinib
CAS:Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Fórmula:C17H20N8O2SPureza:99.89%Forma y color:SoildPeso molecular:400.46RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Fórmula:C29H35N7O4Pureza:97.29% - 99.91%Forma y color:SolidPeso molecular:545.63STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells andFórmula:C18H24Cl2N2O6PtPureza:98%Forma y color:SolidPeso molecular:630.38Cerdulatinib
CAS:Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Forma y color:SolidPeso molecular:445.54Ref: TM-T2487
1mg44,00€2mg55,00€5mg79,00€10mg106,00€25mg185,00€50mg283,00€100mg432,00€200mg605,00€500mg938,00€1mL*10mM (DMSO)86,00€Brevilin A
CAS:Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.Fórmula:C20H26O5Pureza:100% - 99.74%Forma y color:SolidPeso molecular:346.42Ref: TM-T4672
1mg96,00€5mg215,00€10mg369,00€25mg610,00€50mg840,00€100mg1.130,00€500mg2.308,00€1mL*10mM (DMSO)235,00€(Z)-SMI-4a
CAS:(Z)-SMI-4a (TCS PIM-1 4a) is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.Fórmula:C11H6F3NO2SPureza:97.66% - 99.44%Forma y color:SolidPeso molecular:273.23K00135
CAS:K00135 (IMIDAZOPYRIDAZIN 1) is a selective inhibitor of Pim kinases and can be used in studies about gastric cancer and antileukemic therapeutics.Fórmula:C18H18N4OPureza:97.88%Forma y color:SolidPeso molecular:306.36Ref: TM-T27704
1mg185,00€2mg279,00€5mg426,00€10mg627,00€25mg938,00€50mg1.320,00€100mg1.786,00€500mg3.591,00€1mL*10mM (DMSO)415,00€JAK-IN-14
CAS:JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.Fórmula:C19H15FN4OPureza:98.27%Forma y color:SolidPeso molecular:334.35Ref: TM-T9764
1mg139,00€5mg330,00€10mg492,00€25mg797,00€50mg1.103,00€100mg1.491,00€200mg1.985,00€1mL*10mM (DMSO)340,00€STAT5-IN-3
STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer properties. It works by blocking the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites, significantly reducing the expression of the STAT5B protein. This leads to the inhibition of downstream gene transcription, thereby preventing the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 has significant potential in overcoming chemotherapy resistance.Fórmula:C25H27N5OForma y color:SolidPeso molecular:413.51JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFórmula:C19H18N4O3Pureza:97.46% - 99.94%Forma y color:SolidPeso molecular:350.37CEP-33779
CAS:CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.Fórmula:C24H26N6O2SPureza:98.81% - ≥95%Forma y color:SolidPeso molecular:462.57Ref: TM-T6122
1mg46,00€2mg59,00€5mg87,00€10mg144,00€25mg245,00€50mg376,00€100mg560,00€500mg1.216,00€1mL*10mM (DMSO)97,00€JAK1-IN-11
CAS:JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.Fórmula:C26H36N6O4SPureza:98%Forma y color:SolidPeso molecular:528.67Lorpucitinib
CAS:Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.Fórmula:C22H28N6O2Pureza:99.72%Forma y color:SolidPeso molecular:408.5Izencitinib
CAS:Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.Fórmula:C22H26N8Pureza:99.82%Forma y color:SolidPeso molecular:402.50Ref: TM-T35898
1mg88,00€5mg187,00€10mg298,00€25mg597,00€50mg938,00€100mg1.510,00€200mg2.072,00€1mL*10mM (DMSO)207,00€VB1080
VB1080 (compound 12) is a potent PIM inhibitor with IC50 values of 69.5 µM for PIM1, 4996 µM for PIM2, and 9.88 µM for PIM3. Additionally, VB1080 exhibits cytotoxic properties and possesses anthelmintic activity.Fórmula:C27H27N3O3Peso molecular:441.522Pim-1 kinase inhibitor 5
CAS:Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-Fórmula:C22H13Cl2N3OPureza:98%Forma y color:SolidPeso molecular:406.26
